1Anand IS,Fisher LD,Chiang YT, et al.Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT) [J]. Circulation,2003,107 (9); 1278-1283. 被引量：1
2Yasuaki D, Masuo O, Masaya A, et al.Candesartan reduces oxidative stress and inflammation in patients with essential Hypertension. hypertens Res, 2003, 26:691-697. 被引量：1
3Oparil S. Newly emerging pharmacologic differences in angiotensinⅡ receptor blockers[J]. Am J Hypert,2000,13:18S. 被引量：1
4Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study(LIFE): a randomized trial against atenolol [J] .Lancet, 2002,359: 995-1003. 被引量：1
5Julius S, Kjeldsen SE, Weber M. VALUE trial group. outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial[J]. Lanc et, 2004,363 ( 9426 ): 2022-2031. 被引量：1
6Nelson MR, Reid CM, Krum H, et al.Short-term predictors of maintenance of normotension after withdrawal of antigypertensive drugs in the second Australian national blood pressure study(ANBP2) [J] . Am J Hypertens, 2003Jan, 16(1);39-45. 被引量：1
7Pitt B, Segal R, Martinez FA, On behalf of ELITE study investigators. Randomized trial of losartan versus cap in patients over 65 with heart failure(Evaluatiotopril3n of losartan in the elderly study. ELITE) [J] .Lancet, 1997,349:747-752. 被引量：1
8Pitt B,Poole-Wilson PA, Se gal R, et al.Effect of Losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan heart failure survival study ELITE Ⅱ[J] . Lancet, 2000, 355:1582-1587. 被引量：1
9Cohn JN, Tognoni G. 4 Valsartan heart failure trial investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[J] . N Engl J Med, 2001,345: 1667-1675. 被引量：1
10Pfeifer MA, S wedberg K. The CHARM investigators and committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme [J] . Lancet,2003,362(9386) :759-781. 被引量：1
